Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nice Ltd

153.41
-0.8600-0.56%
Pre-market: 154.250.8400+0.55%05:23 EDT
Volume:295.15K
Turnover:45.12M
Market Cap:9.70B
PE:21.40
High:154.23
Open:154.23
Low:151.80
Close:154.27
Loading ...

Northland Securities Sticks to Their Buy Rating for NICE (NICE)

TIPRANKS
·
18 Feb

Nice Ltd expected to post earnings of $2.95 a share - Earnings Preview

Reuters
·
18 Feb

NICE Ltd. (NICE): Among the Cheap Technology Stocks to Buy According to Analysts

Insider Monkey
·
15 Feb

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

GlobeNewswire
·
14 Feb

Press Release: NICE Provides Webcast and Dial-in Details for its Fourth Quarter 2024 Results Teleconference

Dow Jones
·
13 Feb

Vertiv Holdings Co: A Key Exit in Barrow, Hanley, Mewhinney & Strauss's Latest 13F Filing

GuruFocus.com
·
13 Feb

NICE and FDNY Collaborate to Enhance Digital Evidence Management

TIPRANKS
·
10 Feb

NICE Selected by Fire Department of New York to Digitally Transform Evidence Management

Business Wire
·
10 Feb

NICE Ltd. (NICE): Expanding AI-Driven Solutions with Strong Financial Results

Insider Monkey
·
03 Feb

NICE Ltd. (NICE): A Bull Case Theory

Insider Monkey
·
01 Feb

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Business Wire
·
31 Jan

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

GlobeNewswire
·
30 Jan

Is NICE Ltd. (NICE) the Cheap AI Stock to Buy in 2025?

Insider Monkey
·
29 Jan

Nice Faces Risk From Generative AI, Cloud-Based Services, Oppenheimer Says

MT Newswires Live
·
24 Jan

Ed Arce Recommends Vafseo for CKD Dialysis Patients Amid NICE Endorsement and US Market Potential

TIPRANKS
·
24 Jan

RBC Capital Remains a Buy on NICE (NICE)

TIPRANKS
·
23 Jan

NICE Ltd. (NICE): Why Should You Invest In This Undervalued Tech Stock Now?

Insider Monkey
·
22 Jan

Cantor Fitzgerald Initiates NICE at Neutral With $176 Price Target

MT Newswires Live
·
17 Jan

Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

GlobeNewswire
·
16 Jan

NICE vs. PYCR: Which Stock Should Value Investors Buy Now?

Zacks
·
16 Jan